Xenon Pharmaceuticals

XENE

Market cap $3.23B

Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience

VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 77,750 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of October 2, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Xenon Pharmaceuticals Inc. - Special Call Company Participants Ian Mortimer - Interim CFO, President, CEO, Principal Financial Officer, Principal Accounting Officer & Director James Empfield - Executive Vice President of Drug Discovery JP Gilbert Christopher Kenney - Chief Medical Officer Presentation Ian Mortimer Interim CFO, President, CEO, Principal Financial Officer, Principal Accounting Officer & Director Good morning, everyone. My name is Ian Mortimer, I'm the President and CEO of Xenon Pharmaceuticals, and I will be moderating today's session.

VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain.

Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock?

VANCOUVER, British Columbia and BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 55,300 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of August 28, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Xenon Pharmaceuticals is advancing azetukalner in multiple phase 3 trials for focal onset seizures, with topline X-TOLE2 data expected in early 2026. Azetukalner's mechanism and prior dose-dependent efficacy support its potential in epilepsy and neuropsychiatric indications, expanding its market opportunity. Xenon's strong cash position funds operations into 2027, with possible fundraising after key data readouts if results are positive.

XENE's wider Q2 loss highlights its push toward late-stage epilepsy, depression, and bipolar disorder studies with azetukalner.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q2 2025 Earnings Conference Call August 11, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Christopher John Kenney - Chief Medical Officer Darren S. Cline - Chief Commercial Officer and Member of Executive Team Ian C.

– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 – Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated – Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain – Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch – Conference call at 4:30 pm ET today